Mostrar el registro sencillo del ítem
Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database
dc.contributor.author | Udovin, Lucas Daniel | |
dc.contributor.author | Otero-Losada, Matilde | |
dc.contributor.author | Bordet, Sofia | |
dc.contributor.author | Chevalier, Guenson | |
dc.contributor.author | Quarracino, Cecilia | |
dc.contributor.author | Capani, Francisco | |
dc.contributor.author | Perez-Lloret, Santiago | |
dc.date.accessioned | 2021-04-22T03:50:38Z | |
dc.date.available | 2021-04-22T03:50:38Z | |
dc.date.issued | 2021-05 | |
dc.identifier | 10.1016/j.parkreldis.2021.03.007 | |
dc.identifier.issn | 13538020 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12728/8800 | |
dc.description.abstract | Introduction: We explored the potential clinical effects of angiotensin-II AT1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in patients from the Parkinson's Progress Marker Initiative (PPMI) study database. Methods: We included 423 newly diagnosed PD patients, free from antiparkinsonian treatment, from the PPMI. We compared the proportion of patients starting on L-DOPA during the first year of follow-up, and the changes in MDS-UPDRS total score and sub-scores during the first five follow-up years for patients exposed or not to ARBs or ACEIs. Results: Treatment with ARBs did not affect the proportion of patients on L-DOPA during the first year (adjusted OR, 95% CI = 0.26, 0.03–2.18, N.S.) while reduced MDS-UPDRS total score (0.85, 0.76–0.95, p < 0.01). Patients treated with ACEIs experienced no changes in either measure. Conclusions: These results show potential signals for a beneficial effect with ARBs. Further clinical trials are warranted. | es_ES |
dc.language.iso | en | es_ES |
dc.publisher | Elsevier Ltd | es_ES |
dc.subject | Angiotensin II | es_ES |
dc.subject | Angiotensin receptor antagonists | es_ES |
dc.subject | Angiotensin-converting enzyme inhibitors | es_ES |
dc.subject | Disease modification | es_ES |
dc.subject | Neuroprotection | es_ES |
dc.subject | Parkinson's disease | es_ES |
dc.title | Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database | es_ES |
dc.type | Article | es_ES |